Business Context and Reporting Period
Company: Broadstone Net Lease, Inc. (BNL)
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2024
Business Overview: BNL is an industrial-focused, diversified net lease REIT investing in single-tenant commercial properties (industrial, restaurant, retail, healthcare, office). As of September 30, 2024, the portfolio consisted of 773 properties across 44 U.S. states and four Canadian provinces, with 99.0% occupancy and a weighted average remaining lease term of 10.3 years.
Key Financial Metrics
| Metric | Q3 2024 (3 Months) | YTD 2024 (9 Months) | YTD 2023 (9 Months) |
|---|---|---|---|
| Lease Revenues, Net | $108.4 million | $319.7 million | $337.9 million |
| Net Income (GAAP) | $37.3 million | $141.4 million | $156.5 million |
| Net Income Attributable to BNL | $35.6 million | $136.1 million | $149.0 million |
| Diluted EPS | $0.19 | $0.72 | $0.80 |
| FFO (Funds From Operations) | $73.8 million | $220.7 million | $229.2 million |
| AFFO (Adjusted FFO) | $70.2 million | $211.5 million | $206.4 million |
| Net Cash from Operating Activities | N/A | $212.3 million | $210.5 million |
| Total Debt Outstanding | $2.0 billion | $2.0 billion | N/A |
| Net Debt | $1.9 billion | $1.9 billion | N/A |
| Cash and Cash Equivalents | $9.0 million | $9.0 million | N/A |
Material Changes vs. Prior Period
- Revenue Decline: YTD 2024 lease revenues decreased 5.4% compared to YTD 2023. This was primarily driven by a $7.5 million decrease in lease termination fees (present in 2023, absent in 2024), a $5.9 million reduction in straight-line rent recognition due to timing of dispositions, and increased write-offs of accrued rental income.
- Impairment Charges: YTD 2024 saw a significant increase in impairment charges to $31.3 million (vs. $1.5 million in YTD 2023). These charges relate to the strategic decision to sell clinically-oriented healthcare properties as part of a portfolio simplification strategy.
- Gain on Sale: YTD 2024 recognized a $65.0 million gain on the sale of 46 properties, compared to a $48.0 million gain on 9 properties in YTD 2023.
- Net Income: YTD 2024 net income decreased 9.7% to $141.4 million, impacted by higher impairments and lower lease revenues, partially offset by higher gains on sales and lower interest expense.
- Interest Expense: YTD 2024 interest expense decreased 10.8% to $54.5 million due to a lower weighted average cost of borrowings and reduced average outstanding balances on variable-rate debt.
Guidance, Outlook, and Risks
- Portfolio Strategy: Management is executing a healthcare portfolio simplification strategy, aiming to reduce healthcare Annualized Base Rent (ABR) below 10%. Through September 30, 2024, 43 healthcare properties were sold for $289.5 million, with an additional 10 sold subsequently for $49.5 million.
- Investment Activity: YTD 2024 total investments were $381.9 million, including $234.3 million in acquisitions, $92.4 million in development funding, and $52.2 million in transitional capital. The weighted average initial cash capitalization rate for acquisitions was 7.3%.
- Liquidity: The company maintains a strong liquidity position with $874.5 million of available capacity under its $1.0 billion Revolving Credit Facility. Net Debt to Annualized Adjusted EBITDAre ratio stands at 5.0x.
- Dividends: A quarterly distribution of $0.29 per share was declared for Q4 2024, payable in January 2025.
- Risks: Key risks include interest rate volatility (mitigated by swaps), foreign exchange fluctuations on Canadian investments, and the ability to redeploy capital from dispositions at accretive yields in a challenging macroeconomic environment.
Investor Verification Checklist
- Healthcare Dispositions: Verify the completion of the healthcare portfolio simplification strategy and the successful redeployment of proceeds into core industrial, retail, and restaurant assets.
- Impairment Volatility: Monitor future quarters for additional impairment charges related to the remaining clinically-oriented healthcare properties.
- Capitalization Rates: Assess whether new acquisitions continue to achieve the targeted 7.0%+ initial cash capitalization rates in the current market.
- Debt Maturities: Review the debt maturity schedule, noting no material maturities until 2026, and the impact of interest rate swaps on the effective cost of debt.
- Forward Sale Agreements: Track the settlement of the $39.0 million in forward sale agreements under the ATM program scheduled for August/September 2025.